Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 point mutations
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Abstract Exon 20 insertions of HER2, encoded by erb-b2 receptor tyrosine kinase 2 (ERBB2), and other activating HER2 mutations occur in 2% to 4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. Sevabertinib (BAY 2927088) is …
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Biochemical kinase activity of sevabertinib in ERBB and non-ERBB family kinases
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Crystallographic data collection and refinement statistics for the co-crystal structure of wild-type EGFR with sevabertinib
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Sevabertinib inhibition in KinaseProfiler kinase activity platform
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 Exon 20 insertion mutations
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Additional cell viability data of zongertinib and STX-721 in isogenic Ba/F3 cell lines
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Antitumor efficacy of sevabertinib in the subcutaneous CTG-2543 xenografts
Accès ouvert
2026
supplementary-materials
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
NRG1 fusions in cancer cell lines
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Sevabertinib response and sensitivity to ERBB family gene CRISPR knockout or RNAi knockdown
Accès ouvert
2026
other
OpenAlex
Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres
Cell viability in HER2-amplified cancer cell lines treated with sevarbertinib or approved HER2 inhibitors